IMRX News & Events

Stocks had a down Friday to close out a down week after data showed unexpected job cuts and rising unemployment in February. Nonfarm payrolls fell by 92,000 in February, missing the growth of 55,000 that economists predicted, and the unemployment rate rose to 4.4% from 4.3%. Meanwhile, West Texas Intermediate futures broke above $90 per barrel for first time since October 2023 after President Donald Trump said in a Truth Social post that there won't be a deal to end the U.S.-Iran war without an "unconditional surrender."Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:President Trump and Secretary Hegseth met with the CEOs of defense companies today at the White House asthere "will be no deal with Iran except unconditional surrender"Marvellreceived a pair of upgrades and a number of price target hikes from Wall Street firms after itswere strongJPMorgan says Costco's"core story remains intact" following the membership club retailer'sGapshares traded lower after Old Navy and Athletain Q4Day One Biopharmaceuticalsby Servier for $21.50 per share in cash2. WALL STREET CALLS:Marvellwasto Buy at Benchmark and BofA on expectations for accelerating data center demandKarmanto Overweight at Piper SandlerOktato Outperform at BMO CapitalWedbushTrade Deskto Underperform, says impact of OpenAI partnership overestimatedZoetisto Hold from Buy at Nephron Research3. AROUND THE WEB:China near deal to order 500 Boeing737 Max jets, Bloomberg saysStates preparing to challenge planned tie-up of Nexstarwith Tegna, WSJ reportsPrivate equity firms including Blackstoneand TPGhave expressed interest in acquiring Whitestone REIT, Reuters reportsChina has approved Pfizer'sGLP-1 treatment Xianweiying for weight management in adults, Reuters saysMetahired the engineering team from Atma Sciences, the startup that makes the vibe coding app Gizmo, earlier in 2026 to join its Superintelligence Labs, Business Insider reports4. MOVERS:Samsaragained after reportingand providing guidance for Q1 and FY27ASP Isotopesincreased afterQuantum Leap Energy has entered into a non-binding MOU with a large publicly traded U.S. energy companyWestern Alliancedeclined after beingby Jefferies (JEF) that payments of $126.4M owed to the bank pursuant to a forbearance agreement will not be paid as agreedREalloysfell after announcing a 2.7MIngram Microdeclined after announcing a 8.999M5. EARNINGS/GUIDANCE:Algonquin Powersreportedand backed its guidance for FY26Embraerreported, with revenue beating consensusImmuneeringreported, with CEO Ben Zeskind commenting that 2025 was "a transformative year"SunCar Technologyreportedfor Q4Methode Electronicsreported Q3 results andfor FY26INDEXES:The Dow fell 0.95%, or 453.19, to 47,501.55, the Nasdaq lost 1.59%, or 361.31, to 22,387.68, and the S&P 500 declined 1.33%, or 90.69, to 6,740.02.

Stocks are down sharply at midday, adding to weekly declines, after the February jobs data showed unexpected job cuts and rising unemployment. Nonfarm payrolls fell by 92,000 in February, missing the growth of 55,000 that economists predicted, and the unemployment rate rose to 4.4% from 4.3%. Meanwhile, West Texas Intermediate futures broke above $89 per barrel after President Donald Trump said in a Truth Social post that there won't be a deal to end the U.S.-Iran war without an "unconditional surrender."Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:and Secretary Hegseth are said to be meeting with the CEOs of defense companies today at the White House as Trump proclaims there "will be no deal with Iran except unconditional surrender"Marvellreceived aand a number of price target hikes from Wall Street firms after its results and guidance were strongJPMorgan says Costco's"" following the membership club retailer's fiscal Q2 reportGapshares are trading lower after Old Navy and Athletaestimates in Q4Day One Biopharmaceuticalsannounced anby Servier for $21.50 per share in cash2. WALL STREET CALLS:Marvellwasto Buy at Benchmark and BofA on expectations for accelerating data center demandKarmanto Overweight at Piper SandlerOktato Outperform at BMO CapitalWedbushTrade Deskto Underperform, says impact of OpenAI partnership overestimatedZoetisto Hold from Buy at Nephron Research3. AROUND THE WEB:Private equity firms including Blackstoneand TPGhave expressed interest in acquiring Whitestone REIT, Reuters reportsChina has approved Pfizer'sGLP-1 treatment Xianweiying for weight management in adults, Reuters saysCarlyleand CVC have agreed to hand UBSsome of their performance fees in return for the bank selling the firms' products to wealthy individuals, FT saysMetahas hired the engineering team from Atma Sciences, the startup that makes the vibe coding app Gizmo, earlier in 2026 to join its Superintelligence Labs, Business Insider reportsThe Pentagon has notified Anthropic it has determined the company and its products are a risk to the U.S. supply chain, Bloomberg says4. MOVERS:Samsaragains afterand providing guidance for Q1 and FY27ASP Isotopesincreases after announcing Quantum Leap Energy has entered into awith a large publicly traded U.S. energy companyWestern Alliancedeclines after being informed by Jefferies that payments of $126.4M owed to the bank pursuant to a forbearance agreementas agreedREalloysfalls after announcing aIngram Microlower after announcing am5. EARNINGS/GUIDANCE:Algonquin Powersand backed its guidance for FY26Embraer, with revenue beating consensusImmuneering, with CEO Ben Zeskind commenting that "2025 was a transformative year"SunCar Technologyfor Q4Methode Electronicsand narrowed its guidance for FY26INDEXES:Near midday, the Dow was down 1.18%, or 566.51, to 47,388.23, the Nasdaq was down 0.77%, or 176.09, to 22,572.89, and the S&P 500 was down 1.01%, or 69.05, to 6,761.66.

"2025 was a transformative year for Immuneering. We reported 64% overall survival at 12 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP, well above the benchmark for GnP standard of care. We designed atebimetinib with three mechanisms well-established to improve survival, and we believe these survival gains are driven by atebimetinib shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize combinability and performance status," said Ben Zeskind, Ph.D., Chief Executive Officer of Immuneering. "We also made rapid progress in preparation for our pivotal Phase 3 trial in first-line pancreatic cancer patients, MAPKeeper 301, having secured alignment with both the FDA and EMA on our trial design, and we are on track to dose the first patient mid-year. With cash runway expected into 2029, uniquely encouraging clinical data, and a solid pipeline, we are strongly positioned to deliver on our mission to help patients live longer and feel better."